Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Assessment of a Novel Automatic Real-Time PCR Assay on the Cobas 4800 Analyzer as a Screening Platform for Hepatitis C Virus Genotyping in Clinical Practice, Comparison with Massive Sequencing

  • Nieto, Leonardo|||0000-0002-1336-5645
  • Quer, Josep|||0000-0003-0014-084X
  • Ruiz-Ripa, Alicia
  • Tabernero, David|||0000-0002-1146-4084
  • González, Carolina|||0000-0002-0169-5874
  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Vila, Marta|||0000-0001-9303-5189
  • Asensio, Miriam
  • Garcia-Cehic, D.|||0000-0002-0009-038X
  • Ruiz, Gerardo
  • Chen, Qian
  • Ordeig, Laura
  • Llorens, Meritxell
  • Saez, Montserrat
  • Esteban Mur, Juan Ignacio|||0000-0001-5085-917X
  • Esteban, Rafael|||0000-0001-5280-392X
  • Buti, Maria|||0000-0002-0732-3078
  • Pumarola Suñé, Tomàs|||0000-0002-5171-7461
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
The unequivocal identification of hepatitis C virus (HCV) subtypes 1a/1b and genotypes 2 to 6 is required for optimizing the effectiveness of interferon-free, direct-acting antiviral therapies. We compared the performance of a new real-time HCV genotyping assay used on the Cobas 4800 system (C4800) with that of high-resolution HCV subtyping (HRCS). In total, 502 samples were used, including 184 samples from chronic HCV patients (from routine laboratory activity during April 2016), 5 stored samples with double HCV genotype infections for testing the limitations of the method, and 313 samples from a screening protocol implemented in our hospital (from May to August 2016) based on the new method to further determine its genotyping accuracy. A total of 282 samples, including 171 from April 2016 (the 13 remaining had too low of a viral load for HRCS), 5 selected with double infections, and 106 from screening, were analyzed by both methods, and 220 were analyzed only by the C4800. The C4800 correctly subtyped 125 of 126 1a/1b samples, and the 1 remaining sample was reported as genotype 1. The C4800 correctly genotyped 38 of 45 non-1a/1b samples (classified by HRCS), and it reported the remaining 7 samples as indeterminate. One hundred two of 106 non-1a/1b genotype samples that were identified using the C4800 for screening were confirmed by HRCS. In the 4 remaining samples, 3 were correctly reported as genotype 1 (without defining the subtype) and 1 was reported as indeterminate. None of the samples were misgenotyped. Four of 7 samples with double HCV infections were correctly genotyped by the C4800. Excluding the 5 selected double-infected samples, the C4800 showed 95.7% concordant results for genotyping HCVs 2 to 6 and 1a/1b subtyping, and 99.2% concordance for subtyping 1a/1b single infections in clinical samples. To improve laboratory workflow, we propose using the C4800 as a first-line test for HCV genotyping and 1a/1b classification, followed by transferring non-1a/1b samples to a center where HRCS is available, if further characterization is needed.